Results 101 to 110 of about 54,594 (319)
Supplementary Figure from The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner [PDF]
, 2023 Janet K. Peper-Gabriel +18 more
openalex +1 more source
SpyMask enables combinatorial assembly of bispecific binders
bioRxivBispecific antibodies are a successful and expanding therapeutic class, bridging two cell-types or engaging two different molecules on the same cell. Bispecifics unlock avenues towards synergy, resistance evasion, and signaling bias.
Claudia L. Driscoll +2 more
semanticscholar +1 more source
Antibody‐Empowered Nanomedicine for Precise Biomedical Applications
Advanced Science, EarlyView.This review explores strategies for functionalizing nanoparticles with antibodies to construct antibody‐empowered nanomedicine. It discusses the classification of these nanomedicines based on antibody structure, with a specific focus on their biomedical applications in diagnostics, bioimaging, and therapeutics for various diseases.
Chen Chen +7 more
wiley +1 more source
Cell Reports MedicineSummary: Metastatic uveal melanoma is an aggressive disease with poor outcome, which is refractory to immune checkpoint inhibitors. A T cell receptor (TCR)-based CD3 bispecific, tebentafusp, delivers clinical benefit in patients with metastatic uveal ...
Joseph J. Sacco +16 more
doaj +1 more source
Supplementary Fig. S5 from Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design [PDF]
, 2023 Nam-Kyung Lee +3 more
openalex +1 more source
Bispecific antibodies: design, therapy, perspectives
Drug Design, Development and Therapy, 2018 Antibodies (Abs) containing two different antigen-binding sites in one molecule are called bispecific. Bispecific Abs (BsAbs) were first described in the 1960s, the first monoclonal BsAbs were generated in the 1980s by hybridoma technology, and the first article describing the therapeutic use of BsAbs was published in 1992, but the number of papers ...
Sergey Sedykh +3 more
openaire +4 more sources
Engineering Immune Cell to Counteract Aging and Aging‐Associated Diseases
Advanced Science, EarlyView.This review highlights a paradigm shift in which advanced immune cell therapies, initially developed for cancer, are now being harnessed to combat aging. By engineering immune cells to selectively clear senescent cells and remodel pro‐inflammatory tissue microenvironments, these strategies offer a novel and powerful approach to delay age‐related ...
Jianhua Guo +5 more
wiley +1 more source
Extramedullary Disease—Achilles Heel in Myeloma?
American Journal of Hematology, EarlyView.ABSTRACT Despite advances in therapy, extramedullary disease (EMD) remains an aggressive form of multiple myeloma associated with poor outcomes. Patients with true EMD, in which plasmacytomas have become completely independent of bone, have a particularly poor prognosis. The pathogenesis of EMD is driven by complex mechanisms involving loss of adhesion
Shaji Kumar +7 more
wiley +1 more source
A Murine Bispecific Antibody Efficiently Redirects T Cells Against Calr Mutated Stem Cells In Vivo
American Journal of Hematology, EarlyView.ABSTRACT Calreticulin (CALR) mutations are prevalent in 20%–30% of patients with BCR::ABL1‐negative myeloproliferative neoplasms (MPN). Mutant calreticulin (mutCALR), presented by the thrombopoietin receptor (MPL, also known as TPOR or CD110) on the surface of the disease‐initiating MPN progenitors, represents an ideal target for curative ...
Shengen Xiong +5 more
wiley +1 more source
Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors
Molecular Diagnosis & TherapyIn recent years, bispecific antibodies (BsAbs) have emerged as a promising therapeutic strategy against tumors. BsAbs can recruit and activate immune cells, block multiple signaling pathways, and deliver therapeutic payloads directly to tumor sites. This
Yuheng Gu, Qi Zhao
semanticscholar +1 more source